Next-gen immunotherapy: a guide for CGT developers

Innovative cellular immunotherapies are transforming cancer treatment, but challenges remain in analytics, process development, manufacturing, and scaling. In this discussion, Charles River Laboratories’ Alex Sargent (Director of Process Development) shares strategies to streamline cell therapy development, accelerate the path to IND, and optimize workflows for regulatory approval.

Institutions

Charles River Laboratories (Germany) (DE)

Publication Details

Journal: Cell and Gene Therapy Insights
Published: 2025-05-09
DOI: https://doi.org/10.18609/cgti.2025.056
Primary Topic: CAR-T cell therapy research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Next-gen immunotherapy: a guide for CGT developers

May 9, 2025

Cell and Gene Therapy Insights

CAR-T cell therapy research

article

Next-gen immunotherapy: a guide for CGT developers

May 9, 2025article en

Abstract

Cell and Gene Therapy InsightsVol. 11(4)

Charles River Laboratories (Germany) (DE)

Openalex Percentile: Top 32%

CAR-T cell therapy research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Next-gen immunotherapy: a guide for CGT developers · Cell and Gene Therapy Insights (2025) | TGRS Research Map | TGRS